Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- My D88 NTerm Nterminal Cterminal tollinterleukin1 nonmyeloid IL6 TLR1 TLR2 TLR4 TLR5 TLR6 IL1R Myd 88 leucinetoproline TLR7 TLR8 TLR9
- Product Overview:
MyD88 is an adaptor protein involved in the innate immune response.{58195,58196} It is composed of an N-terminal death domain, intermediate domain, and C-terminal toll-interleukin-1 receptor (TIR) domain.{58195} It is expressed in both myeloid and non-myeloid tissues, and its expression can be induced by immune-related factors, such as IL-6, LPS, and IFNs.{58196} As an adaptor protein, the TIR domain of MyD88 interacts with the TIR domain of toll-like receptor 1 (TLR1), -2, -4, -5, and -6, and IL-1 receptor (IL-1R) at the plasma membrane and TLR7, -8, and -9 at the endosomal membrane, while the MyD88 death domain interacts with IL-1R-associated kinases (IRAKs).{58195,58199} In this way, MyD88 translates signals from TLRs and IL-1Rs to IRAKs, inducing signaling that leads to activation of NF-?B and subsequent cytokine production, as well as MAPK signaling.{58195,58196} MyD88 is associated with inflammatory carcinogenesis but is also associated with protection from oncogenic pathogens.{58197} Mice deficient for Myd88 are protected from endotoxic shock induced by the TLR4 agonist LPS but have an increased susceptibility to bacterial pathogens and parasites.{58195} A leucine-to-proline mutation at position 265 of MYD88, within the TIR domain, is associated with certain cancers, including Waldenström’s macroglobulinemia and activated B cell diffuse large B cell lymphomas.{58198} Cayman’s MyD88 (N-Term) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.